1. Home
  2. TRVI vs ETG Comparison

TRVI vs ETG Comparison

Compare TRVI & ETG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

SELL

Current Price

$12.50

Market Cap

1.8B

Sector

Health Care

ML Signal

SELL

Logo Eaton Vance Tax-Advantaged Global Dividend Income Fund of Beneficial Interest

ETG

Eaton Vance Tax-Advantaged Global Dividend Income Fund of Beneficial Interest

SELL

Current Price

$22.89

Market Cap

1.8B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
TRVI
ETG
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2019
2003

Fundamental Metrics

Financial Performance
Metric
TRVI
ETG
Price
$12.50
$22.89
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $28.18
N/A
AVG Volume (30 Days)
★ 2.5M
76.8K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 31.91
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.82
$19.34
52 Week High
$20.22
$24.71

Technical Indicators

Market Signals
Indicator
TRVI
ETG
Relative Strength Index (RSI) 36.03 44.12
Support Level $11.70 $22.59
Resistance Level $13.55 $23.51
Average True Range (ATR) 0.66 0.32
MACD 0.13 0.00
Stochastic Oscillator 44.81 26.02

Price Performance

Historical Comparison
TRVI
ETG

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

About ETG Eaton Vance Tax-Advantaged Global Dividend Income Fund of Beneficial Interest

Eaton Vance Tax Advgd Gbl Div Inc Fd is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of aerospace and defense, capital markets, diversified telecommunication services, electrical equipment, biotechnology, banks, and other areas.

Share on Social Networks: